基线PINP对treatment-naïve原发性骨质疏松患者使用罗莫索单抗、特立帕肽和地诺单抗增加BMD的影响：一项回顾性队列研究。

IF 3.6 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Bone Pub Date : 2025-09-03 DOI:10.1016/j.bone.2025.117627

Yuki Etani , Takaaki Noguchi , Toshitaka Yukishima , Tomonori Kobayakawa , Masafumi Kashii , Gensuke Okamura , Atsushi Goshima , Makoto Hirao , Taihei Miura , Takuya Kurihara , Yuji Fukuda , Atsushi Sugimoto , Seiji Okada , Ken Nakata , Kosuke Ebina

{"title":"基线PINP对treatment-naïve原发性骨质疏松患者使用罗莫索单抗、特立帕肽和地诺单抗增加BMD的影响：一项回顾性队列研究。","authors":"Yuki Etani , Takaaki Noguchi , Toshitaka Yukishima , Tomonori Kobayakawa , Masafumi Kashii , Gensuke Okamura , Atsushi Goshima , Makoto Hirao , Taihei Miura , Takuya Kurihara , Yuji Fukuda , Atsushi Sugimoto , Seiji Okada , Ken Nakata , Kosuke Ebina","doi":"10.1016/j.bone.2025.117627","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis.</div></div><div><h3>Methods</h3><div>This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (<em>n</em> = 310), TPTD (<em>n</em> = 70), or DMAb (<em>n</em> = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months.</div></div><div><h3>Results</h3><div>In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group.</div></div><div><h3>Conclusion</h3><div>ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"201 ","pages":"Article 117627"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study\",\"authors\":\"Yuki Etani , Takaaki Noguchi , Toshitaka Yukishima , Tomonori Kobayakawa , Masafumi Kashii , Gensuke Okamura , Atsushi Goshima , Makoto Hirao , Taihei Miura , Takuya Kurihara , Yuji Fukuda , Atsushi Sugimoto , Seiji Okada , Ken Nakata , Kosuke Ebina\",\"doi\":\"10.1016/j.bone.2025.117627\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis.</div></div><div><h3>Methods</h3><div>This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (<em>n</em> = 310), TPTD (<em>n</em> = 70), or DMAb (<em>n</em> = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months.</div></div><div><h3>Results</h3><div>In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group.</div></div><div><h3>Conclusion</h3><div>ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.</div></div>\",\"PeriodicalId\":9301,\"journal\":{\"name\":\"Bone\",\"volume\":\"201 \",\"pages\":\"Article 117627\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bone\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S875632822500239X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S875632822500239X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：探讨原发性骨质疏松患者接受罗莫单抗（ROMO）、特利帕肽（TPTD）和地诺单抗（DMAb）治疗后，基线前胶原总n端前肽（PINP）水平对骨密度（BMD）升高的影响。方法:这个多中心回顾性队列研究包括462名首次治疗患者(88.7 %女性,平均年龄75.5 年;基线BMD t指数:腰椎(LS), -3.0;全髋关节(TH), -2.7)谁发起ROMO治疗(n = 310),TPTD (n = 70),或DMAb (n = 82)。根据基线总PINP水平将患者分为低（≤70.1 μg/L）组和高（> 70.1 μg/L）组。在使用治疗加权逆概率调整基线特征后，在12 个月时评估骨密度的变化。结果：在低PINP组，ROMO和TPTD的LS BMD增加相似；在高PINP组中，ROMO导致LS BMD的增加大于TPTD。无论PINP水平如何，ROMO导致thbmd比TPTD更大的增加。与DMAb相比，在低PINP组中，ROMO导致LS BMD和TH BMD增加更大，而在高PINP组中没有观察到显著差异。结论：在所有PINP水平下，ROMO均表现出LS和TH BMD的显著增加。TPTD导致的LS骨密度增加与低PINP组ROMO患者相当。与高PINP组的ROMO患者相比，DMAb导致LS和TH BMD的增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

Purpose

To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis.

Methods

This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (n = 310), TPTD (n = 70), or DMAb (n = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months.

Results

In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group.

Conclusion

ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bone 医学-内分泌学与代谢

CiteScore

8.90

自引率

4.90%

发文量

264

审稿时长

30 days

期刊介绍： BONE is an interdisciplinary forum for the rapid publication of original articles and reviews on basic, translational, and clinical aspects of bone and mineral metabolism. The Journal also encourages submissions related to interactions of bone with other organ systems, including cartilage, endocrine, muscle, fat, neural, vascular, gastrointestinal, hematopoietic, and immune systems. Particular attention is placed on the application of experimental studies to clinical practice.